STAT Plus: Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst
Biotech: Disrupted.
As the number of Covid-19 cases expand globally, every corner of the biotech industry will be impacted in some way. There will be office interruptions, delays in drug development and clinical trials, extensions of regulatory reviews, and limits on new drug launches. Sales of certain older drugs will drop along with prescriptions. Expect investor and financing challenges, too.
